Want to see IN:ANUHPHR full AI Analyst Report?
ANUHPHR Stock Chart & Stats
₹77.53
-₹3.95(-1.77%)
At close: 4:00 PM EST
₹77.53
-₹3.95(-1.77%)
Day’s Range― - ―
52-Week Range₹66.72 - ₹99.50
Previous CloseN/A
Volume12.53K
Average Volume (3M)12.87K
Market Cap
₹7.75B
Enterprise Value₹2.83B
Total Cash (Recent Filing)₹135.33M
Total Debt (Recent Filing)₹2.27M
Price to Earnings (P/E)17.5
Beta0.74
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.94%
Share Statistics
EPS (TTM)2.00
Shares Outstanding100,224,000
10 Day Avg. Volume10,849
30 Day Avg. Volume12,871
Financial Highlights & Ratios
PEG Ratio-1.25
Price to Book (P/B)1.91
Price to Sales (P/S)0.87
P/FCF Ratio-61.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong revenue expansion indicates continued demand for the company’s API products and increasing commercial activity. If this growth persists, it can improve scale, support more efficient operations, and provide a broader base from which to rebuild profitability over the coming quarters.
Conservative Balance SheetNear-zero leverage gives Anuh Pharma substantial financial flexibility and reduces exposure to interest costs or refinancing pressure. Growing equity and assets further support resilience, allowing the company to sustain operations and fund opportunities without relying heavily on debt.
Specialized API Business ModelA focused API manufacturing model provides a defined role in pharmaceutical supply chains, serving formulation companies and other drug manufacturers. Concentration on specialized therapeutic inputs can support repeat industry demand and operational expertise across the company’s product portfolio.
Bears Say
Margin CompressionThe sharp decline in gross and net margins shows that higher sales are currently producing less profit per unit of revenue. Persistent margin pressure would reduce earnings scalability, weaken returns on growth, and make future results more sensitive to product mix and operating costs.
Negative Cash GenerationNegative operating and free cash flow indicates that reported earnings are not currently converting into cash reliably. Until cash generation normalizes, the company may have less internally generated funding for investment and may face greater pressure from working-capital or investment requirements.
Earnings DeteriorationLower net income despite stronger revenue points to weakening earnings quality and reduced operating leverage in the latest year. If this pattern continues, it could limit shareholder returns, diminish the benefit of scale, and make revenue growth less valuable without a recovery in profitability.
Anuh Pharma Limited News
ANUHPHR FAQ
What was Anuh Pharma Limited’s price range in the past 12 months?
Anuh Pharma Limited lowest stock price was ₹66.72 and its highest was ₹99.50 in the past 12 months.
What is Anuh Pharma Limited’s market cap?
Anuh Pharma Limited’s market cap is ₹7.75B.
When is Anuh Pharma Limited’s upcoming earnings report date?
Anuh Pharma Limited’s upcoming earnings report date is Nov 13, 2026 which is in 17 days.
How were Anuh Pharma Limited’s earnings last quarter?
Anuh Pharma Limited released its earnings results on Aug 07, 2026. The company reported ₹1.14 earnings per share for the quarter.
Is Anuh Pharma Limited overvalued?
According to Wall Street analysts Anuh Pharma Limited’s price is currently Overvalued.
Does Anuh Pharma Limited pay dividends?
Anuh Pharma Limited pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 1.94%. See more information on Anuh Pharma Limited dividends here
What is Anuh Pharma Limited’s EPS estimate?
Anuh Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anuh Pharma Limited have?
Anuh Pharma Limited has 100,224,000 shares outstanding.
What happened to Anuh Pharma Limited’s price movement after its last earnings report?
Anuh Pharma Limited reported an EPS of ₹1.14 in its last earnings report. Following the earnings report the stock price went up 1.166%.
Which hedge fund is a major shareholder of Anuh Pharma Limited?
Currently, no hedge funds are holding shares in IN:ANUHPHR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Anuh Pharma Limited
Anuh Pharma Ltd. is an Indian enterprise specializing in the manufacturing and distribution of bulk drugs and various chemical compounds. The company provides a comprehensive selection of active pharmaceutical ingredients (APIs), encompassing macrolides, anti-tuberculosis agents, antibacterials, anti-asthmatics, anti-diabetic compounds, intermediates, expectorants, quinolones, anti-malarials, anti-gout medications, antibiotics, anti-platelet drugs, and antihistamines. Additionally, it produces corticosteroids valued for their anti-inflammatory, immunosuppressant, anti-pruritic, and anti-mitotic actions. Anuh Pharma is also engaged in developing new products within therapeutic categories such as coagulants, gastrointestinal treatments, anticonvulsants, and cholesterol-reducing medications. Its products are sold both domestically and to international markets. The company, established in 1960, maintains its headquarters in Mumbai, India.
Technical Analysis
Albert David Ltd
―
Kilitch Drugs (India) Limited
―
Sigachi Industries Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―